Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study

Author： Schmid P.   Krocker J.   Morack G.   Heilmann V.   Blohmer J.-U.   Michniewicz K.   Köhler G.   Schaller-Kranz T.   Possinger K.   Elling D.  

Publisher： Springer Publishing Company

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.130, Iss.11, 2004-11, pp. : 657-663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

By Lyman Gary   Green Stephanie   Ravdin Peter   Geyer Charles   Russell Christy   Balcerzak Stanley   Thomas Budd G.   Martino Silvana  

Breast Cancer Research and Treatment, Vol. 85, Iss. 2, 2004-05 ,pp. : 143-150

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

By Kim Jong   Sohn Sang   Song Hong   Kwon Ki-Young   Do Young   Lee Kyung   Hyun Myung   Ryoo Hun   Bae Sung   Park Keon   Baek Jin   Lee Won   Chung Joo   Cho Goon   Sohn Chang-Hak   Jang Jung   Chung Ho   Yu Wansik  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 6, 2007-11 ,pp. : 863-869

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer

By Ueda Yuji   Yamagishi Hisakazu   Ichikawa Daisuke   Okamoto Kazuma   Otsuji Eigo   Morii Jun   Koizumi Kinya   Kakihara Naoki   Shimotsuma Masataka   Yamashita Tetsuro   Taniguchi Fumihiro   Aragane Hideki   Nishi Hiroshi   Itokawa Yoshiki   Morita Satoshi   Sakamoto Junichi  

Gastric Cancer, Vol. 13, Iss. 3, 2010-08 ,pp. : 149-154

Springer Publishing Company

Access to resources Recommend Favorite

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

By Lobo Christopher   Lopes Gilberto   Baez Odalys   Castrellon Aurelio   Ferrell Annapoorna   Higgins Connie   Hurley Erin   Hurley Judith   Reis Isildinha   Richman Stephen   Seo Pearl   Silva Orlando   Slingerland Joyce   Tukia Keleni   Welsh Catherine   Glück Stefan  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 427-435

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

By Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 429-437

Springer Publishing Company

Access to resources Recommend Favorite